Uterine leiomyomas (or fibroids) represent the most common tumor affecting up to 80% of reproductive-age women. Epidemiological studies consistently indicate a positive association between exposure to endocrine-disrupting phthalates and leiomyoma risk; however, the underlying mechanisms remain unclear. Here, we demonstrate that the ubiquitous environmental pollutant mono-(2-ethyl-5-hydroxyhexyl) phthalate [MEHHP, the major metabolite of di-(2-ethylhexyl) phthalate] promotes… Continue reading Mono-(2-ethyl-5-hydroxyhexyl) phthalate promotes uterine leiomyoma cell survival through tryptophan-kynurenine-AHR pathway activation
Tag: uterus
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
Uterine fibroids are common non-cancerous neoplasm that cause heavy menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone receptor antagonist taken once per day that dose-dependently suppresses gonadal steroids and might reduce uterine-fibroid-associated signs. Two phase 3 trials were conducted to confirm the efficacy and safety of linzagolix at full-suppression (200 mg) and… Continue reading Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
2 Medical News 